Anti-obesity drugs

A review about their effects and their safety

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Introduction: Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs have been withdrawn because of their adverse effects. In fact, orlistat is the only available long-term treatment for obesity. Areas covered: The efficacy and safety of long-term drug therapy is very important in the management obesity; for this reason, the authors decided to conduct a review on the efficacy and safety of current, past and future pharmacotherapies for weight loss. Expert opinion: Orlistat is a good choice for the treatment of obesity, because of its safety on cardiovascular events and its positive effects on diabetic control, even if it is not as effective as rimonabant or sibutramine in reducing body weight. Regarding emerging anti-obesity therapies in diabetic people, we currently have drugs that have already been marketed including the glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide; other than improving glycemic control, they also suppress appetite reducing body weight. Moreover, some other drugs are currently in study such as tesofensine, phentermine + topiramate, bupropion + naltrexone and bupropion + zonisamide. Furthermore, several additional gut hormone-based treatments for obesity are under investigation in Phase II and III clinical trials, with particular focus on ghrelin, peptide YY, pancreatic polypeptide, amylin and oxyntomodulin.

Original languageEnglish
Pages (from-to)459-471
Number of pages13
JournalExpert Opinion on Drug Safety
Volume11
Issue number3
DOIs
Publication statusPublished - May 2012

Fingerprint

Anti-Obesity Agents
rimonabant
sibutramine
Obesity
Safety
Bupropion
zonisamide
Oxyntomodulin
Phentermine
Body Weight
Peptide YY
Islet Amyloid Polypeptide
Amphetamines
Pancreatic Polypeptide
Drug Therapy
Phase III Clinical Trials
Phase II Clinical Trials
Naltrexone
Ghrelin
Expert Testimony

Keywords

  • Emerging therapy
  • Obesity management
  • Orlistat
  • Rimonabant
  • Sibutramine

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Anti-obesity drugs : A review about their effects and their safety. / Derosa, Giuseppe; Maffioli, Pamela.

In: Expert Opinion on Drug Safety, Vol. 11, No. 3, 05.2012, p. 459-471.

Research output: Contribution to journalArticle

@article{8dac9e9223774458ae318c0ef04d3c1d,
title = "Anti-obesity drugs: A review about their effects and their safety",
abstract = "Introduction: Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs have been withdrawn because of their adverse effects. In fact, orlistat is the only available long-term treatment for obesity. Areas covered: The efficacy and safety of long-term drug therapy is very important in the management obesity; for this reason, the authors decided to conduct a review on the efficacy and safety of current, past and future pharmacotherapies for weight loss. Expert opinion: Orlistat is a good choice for the treatment of obesity, because of its safety on cardiovascular events and its positive effects on diabetic control, even if it is not as effective as rimonabant or sibutramine in reducing body weight. Regarding emerging anti-obesity therapies in diabetic people, we currently have drugs that have already been marketed including the glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide; other than improving glycemic control, they also suppress appetite reducing body weight. Moreover, some other drugs are currently in study such as tesofensine, phentermine + topiramate, bupropion + naltrexone and bupropion + zonisamide. Furthermore, several additional gut hormone-based treatments for obesity are under investigation in Phase II and III clinical trials, with particular focus on ghrelin, peptide YY, pancreatic polypeptide, amylin and oxyntomodulin.",
keywords = "Emerging therapy, Obesity management, Orlistat, Rimonabant, Sibutramine",
author = "Giuseppe Derosa and Pamela Maffioli",
year = "2012",
month = "5",
doi = "10.1517/14740338.2012.675326",
language = "English",
volume = "11",
pages = "459--471",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Anti-obesity drugs

T2 - A review about their effects and their safety

AU - Derosa, Giuseppe

AU - Maffioli, Pamela

PY - 2012/5

Y1 - 2012/5

N2 - Introduction: Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs have been withdrawn because of their adverse effects. In fact, orlistat is the only available long-term treatment for obesity. Areas covered: The efficacy and safety of long-term drug therapy is very important in the management obesity; for this reason, the authors decided to conduct a review on the efficacy and safety of current, past and future pharmacotherapies for weight loss. Expert opinion: Orlistat is a good choice for the treatment of obesity, because of its safety on cardiovascular events and its positive effects on diabetic control, even if it is not as effective as rimonabant or sibutramine in reducing body weight. Regarding emerging anti-obesity therapies in diabetic people, we currently have drugs that have already been marketed including the glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide; other than improving glycemic control, they also suppress appetite reducing body weight. Moreover, some other drugs are currently in study such as tesofensine, phentermine + topiramate, bupropion + naltrexone and bupropion + zonisamide. Furthermore, several additional gut hormone-based treatments for obesity are under investigation in Phase II and III clinical trials, with particular focus on ghrelin, peptide YY, pancreatic polypeptide, amylin and oxyntomodulin.

AB - Introduction: Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs have been withdrawn because of their adverse effects. In fact, orlistat is the only available long-term treatment for obesity. Areas covered: The efficacy and safety of long-term drug therapy is very important in the management obesity; for this reason, the authors decided to conduct a review on the efficacy and safety of current, past and future pharmacotherapies for weight loss. Expert opinion: Orlistat is a good choice for the treatment of obesity, because of its safety on cardiovascular events and its positive effects on diabetic control, even if it is not as effective as rimonabant or sibutramine in reducing body weight. Regarding emerging anti-obesity therapies in diabetic people, we currently have drugs that have already been marketed including the glucagon-like peptide-1 (GLP-1) receptor agonists exenatide and liraglutide; other than improving glycemic control, they also suppress appetite reducing body weight. Moreover, some other drugs are currently in study such as tesofensine, phentermine + topiramate, bupropion + naltrexone and bupropion + zonisamide. Furthermore, several additional gut hormone-based treatments for obesity are under investigation in Phase II and III clinical trials, with particular focus on ghrelin, peptide YY, pancreatic polypeptide, amylin and oxyntomodulin.

KW - Emerging therapy

KW - Obesity management

KW - Orlistat

KW - Rimonabant

KW - Sibutramine

UR - http://www.scopus.com/inward/record.url?scp=84860163107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860163107&partnerID=8YFLogxK

U2 - 10.1517/14740338.2012.675326

DO - 10.1517/14740338.2012.675326

M3 - Article

VL - 11

SP - 459

EP - 471

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 3

ER -